Booklet Updates - Lymphoma
The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
Cutaneous T-Cell Lymphoma
- In August 2024, the Food and Drug Administration (FDA) approved denileukin diftitox-cxdl (Lymphir™) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Hodgkin Lymphoma
No updates
Non-Hodgkin Lymphoma
- In June 2024, the Food and Drug Administration (FDA) expanded the indication of epcoritamab-bysp (Epkinly®) to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
The Lymphoma Guide: Information for Patients and Caregivers
- In June 2024, the Food and Drug Administration (FDA) expanded the indication of epcoritamab-bysp (Epkinly®) to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.